Home Cart Sign in  
Chemical Structure| 348086-71-5 Chemical Structure| 348086-71-5

Structure of Pritelivir
CAS No.: 348086-71-5

Chemical Structure| 348086-71-5

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

BAY 57-1293 represents a potent inhibitor of herpes simplex virus (HSV) that target the virus helicase primase complex.

Synonyms: AIC316; BAY 57-1293

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Pritelivir

CAS No. :348086-71-5
Formula : C18H18N4O3S2
M.W : 402.49
SMILES Code : O=C(N(C1=NC(C)=C(S(=O)(N)=O)S1)C)CC2=CC=C(C3=NC=CC=C3)C=C2
Synonyms :
AIC316; BAY 57-1293
MDL No. :MFCD28347970
InChI Key :IVZKZONQVYTCKC-UHFFFAOYSA-N
Pubchem ID :491941

Safety of Pritelivir

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Related Pathways of Pritelivir

DNA

Isoform Comparison

Biological Activity

In Vitro:

Cell Line
Concentration Treated Time Description References
Primary keratinocytes 0.05–15 μM 24 hours Evaluate the cytotoxicity of Pritelivir on primary keratinocytes, showing no significant toxicity at concentrations ranging from 0.05–15 μmol/L. PMC7100788
Vero cells 0.39 μM (EC50), 0.81 μM (EC90) 48 hours Determine the EC50 and EC90 values of Pritelivir against resistant mutant cl-2-r1-Rec strain PMC4068558
Vero cells 0.01 μM (EC50), 0.03 μM (EC90) 48 hours Determine the EC50 and EC90 values of Pritelivir against wild-type HSV-1 SC16 cl-2 strain PMC4068558
Vero cells 20 nM Inhibited replication of HSV-1 and HSV-2 with a selectivity index of 2500 PMC127257

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
Pigtailed macaques Pigtailed macaque model Vaginal administration 5.36 mg/IVR Continuous for 28 days To evaluate the safety and pharmacokinetics of Pritelivir in pigtailed macaques, showing median plasma concentrations of 18,700 pg/mL, and vaginal fluid concentrations of 632,327.9 pg/mL (proximal) and 171,289.3 pg/mL (distal). PMC11866343
Mice HSV infection model Oral 0.5 mg/kg Once daily for 5 days To evaluate the therapeutic effect of Pritelivir on HSV infection, results showed that Pritelivir was more effective than valacyclovir in treating HSV infections. PMC9620171
BALB/c mice Murine neck skin infection model Oral gavage 0.5, 1.0, 5.0, 10, 15, 60 mg/kg Once daily for 4 or 8 days Evaluate the efficacy of Pritelivir in a murine HSV-1 infection model, including treatment effects on wild-type and resistant mutant strains PMC4068558
BALB/c mice Lethal infection models of HSV-1 and HSV-2 Oral 0.3 to 30 mg/kg, twice daily Twice daily for 7 days To evaluate the in vivo antiviral activity of Pritelivir against HSV-1 and HSV-2, including acyclovir-resistant strains. Results showed that Pritelivir significantly improved survival rates in infected mice and remained effective even when treatment was delayed for 72 hours. PMC5743594

Clinical Trial:

NCT Number Conditions Phases Recruitment Completion Date Locations
NCT05844436 HSV AVAILABLE - -

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.48mL

0.50mL

0.25mL

12.42mL

2.48mL

1.24mL

24.85mL

4.97mL

2.48mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2

References

 

Historical Records

Categories